Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference

"Myriad is very much a player in the field of companion diagnostics," Myriad Genetics CEO Peter Meldrum told investors at the Goldman Sachs annual global healthcare conference earlier this month.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.